Jonathan R. T. Davidson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan R. T. Davidson has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Kathryn M. Connor
Department of Psychiatry, Duke University, Durham, North Carolina, USA
2 shared publicationsRosario B. Hidalgo
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
2 shared publicationsAndrew Korotzer
Forest Research Institute, Jersey City, New Jersey
1 shared publicationAnjana Bose
Forest Research Institute, Jersey City, New Jersey
1 shared publicationBarbara Crockett
Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina U.S.A.
1 shared publicationDavid Hackett
Wyeth‐Ayerst Research, Paris, France
1 shared publication
Latest Publications
- 1 January 2004
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 19 (4) , 234-240
Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study
Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (18 years or older) who met DSM‐IV criteria for GAD, with baseline Hamilton Rating Scale for Anxiety (HAMA) scores≥18, were randomly assigned to double blind treatment with escitalopram (10 mg/day for the first 4 weeks and then flexibly dosed from 10–20 mg/day) or placebo for 8 weeks, following a 1‐week, single‐blind, placebo lead‐in period. The primary efficacy variable was the mean change from baseline in total HAMA score at Week 8. The escitalopram group (N=158) showed a statistically significant, and clinically relevant, greater improvement at endpoint compared with placebo (N=157) in all prospectively defined efficacy parameters. Significant improvement in HAMA total score and HAMA psychic anxiety subscale score for the escitalopram‐treated group vs. the placebo‐treated group was observed beginning at Week 1 and at each study visit thereafter. Mean changes from baseline to Week 8 on the HAMA total score using a last‐observation‐carried‐forward (LOCF) approach were −11.3 for escitalopram and −7.4 for placebo (P<.001). Response rates at Week 8 were 68% for escitalopram and 41% for placebo (P<.01) for completers, and 58% for escitalopram and 38% for placebo LOCF values (P<.01). Treatment with escitalopram was well tolerated, with low rates of reported adverse events and an incidence of discontinuation due to adverse events not statistically different from placebo (8.9% vs. 5.1%; P=.27). Escitalopram 10–20 mg/day is effective, safe, and well tolerated in the treatment of patients with GAD. Depression and Anxiety 00:000–000, 2004.
- 1 January 2004
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 19 (4) , 234-240
Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study
Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. This study was designed to evaluate the efficacy and tolerability of escitalopram in the treatment of generalized anxiety disorder (GAD). Outpatients (18 years or older) who met DSM‐IV criteria for GAD, with baseline Hamilton Rating Scale for Anxiety (HAMA) scores≥18, were randomly assigned to double blind treatment with escitalopram (10 mg/day for the first 4 weeks and then flexibly dosed from 10–20 mg/day) or placebo for 8 weeks, following a 1‐week, single‐blind, placebo lead‐in period. The primary efficacy variable was the mean change from baseline in total HAMA score at Week 8. The escitalopram group (N=158) showed a statistically significant, and clinically relevant, greater improvement at endpoint compared with placebo (N=157) in all prospectively defined efficacy parameters. Significant improvement in HAMA total score and HAMA psychic anxiety subscale score for the escitalopram‐treated group vs. the placebo‐treated group was observed beginning at Week 1 and at each study visit thereafter. Mean changes from baseline to Week 8 on the HAMA total score using a last‐observation‐carried‐forward (LOCF) approach were −11.3 for escitalopram and −7.4 for placebo (P<.001). Response rates at Week 8 were 68% for escitalopram and 41% for placebo (P<.01) for completers, and 58% for escitalopram and 38% for placebo LOCF values (P<.01). Treatment with escitalopram was well tolerated, with low rates of reported adverse events and an incidence of discontinuation due to adverse events not statistically different from placebo (8.9% vs. 5.1%; P=.27). Escitalopram 10–20 mg/day is effective, safe, and well tolerated in the treatment of patients with GAD. Depression and Anxiety 00:000–000, 2004.
- 7 August 2002
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 16 (1) , 4-13
Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms
Venlafaxine, a serotonin and norepinephrine reuptake inhibitor (SNRI), produces significantly higher remission rates in depressed patients than do the selective serotonin reuptake inhibitors (SSRIs). In this analysis of pooled data, we explored the relationship between differences in treatment efficacy, early improvement of symptoms, and severity of baseline anxiety in depressed patients treated with either venlafaxine or fluoxetine. A pooled analysis was performed on data from 1,454 outpatients with major depression from five double‐blind, randomized studies comparing the 6‐week efficacy of venlafaxine (542 patients) with fluoxetine (555 patients). The Hamilton rating scale for depression (HAM‐D) total and item scores were analyzed at different treatment times up to 6 weeks. Venlafaxine and fluoxetine both produced statistically significant higher response and remission rates compared with placebo starting from week 2 for response and weeks 3 to 4 for remission. Venlafaxine was statistically significantly superior to fluoxetine from week 3 until week 6 in respect of response rate, and from week 2 until week 6 for remission rate. After 1 week of treatment, greater improvement in individual symptoms was observed in the depressed mood, suicide, and psychic anxiety items of the HAM‐D scale for both venlafaxine‐ and fluoxetine‐treated patients compared with placebo. Improvement in psychic anxiety was statistically significantly greater with venlafaxine than with fluoxetine. The presence of baseline psychic anxiety correlated significantly to treatment outcome when analyzing the remission rates. In depressed patients with moderate anxiety (HAM‐D psychic anxiety score ≤2), venlafaxine statistically significantly increased remission rates compared with placebo from week 4 until week 6, while a significant effect of fluoxetine on remission rates was observed starting at week 6. Remission rates in the severely anxious depressed patients (score >2) were statistically significantly higher with venlafaxine than placebo starting from week 3 until the end of the study period, but no difference could be observed between fluoxetine and placebo. Baseline severity of psychic anxiety had a significant impact on remission rates after treatment of patients diagnosed with depression. Venlafaxine's superior remission rates in the more severely anxious patients and its ability to improve psychic anxiety as early as week 1 compared with fluoxetine suggest that venlafaxine's early efficacy on anxiety symptoms may be the basis for its superior efficacy in depression. Depression and Anxiety 16:4–13, 2002. © 2002 Wiley‐Liss, Inc.
- 7 August 2002
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 16 (1) , 4-13
Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms
Venlafaxine, a serotonin and norepinephrine reuptake inhibitor (SNRI), produces significantly higher remission rates in depressed patients than do the selective serotonin reuptake inhibitors (SSRIs). In this analysis of pooled data, we explored the relationship between differences in treatment efficacy, early improvement of symptoms, and severity of baseline anxiety in depressed patients treated with either venlafaxine or fluoxetine. A pooled analysis was performed on data from 1,454 outpatients with major depression from five double‐blind, randomized studies comparing the 6‐week efficacy of venlafaxine (542 patients) with fluoxetine (555 patients). The Hamilton rating scale for depression (HAM‐D) total and item scores were analyzed at different treatment times up to 6 weeks. Venlafaxine and fluoxetine both produced statistically significant higher response and remission rates compared with placebo starting from week 2 for response and weeks 3 to 4 for remission. Venlafaxine was statistically significantly superior to fluoxetine from week 3 until week 6 in respect of response rate, and from week 2 until week 6 for remission rate. After 1 week of treatment, greater improvement in individual symptoms was observed in the depressed mood, suicide, and psychic anxiety items of the HAM‐D scale for both venlafaxine‐ and fluoxetine‐treated patients compared with placebo. Improvement in psychic anxiety was statistically significantly greater with venlafaxine than with fluoxetine. The presence of baseline psychic anxiety correlated significantly to treatment outcome when analyzing the remission rates. In depressed patients with moderate anxiety (HAM‐D psychic anxiety score ≤2), venlafaxine statistically significantly increased remission rates compared with placebo from week 4 until week 6, while a significant effect of fluoxetine on remission rates was observed starting at week 6. Remission rates in the severely anxious depressed patients (score >2) were statistically significantly higher with venlafaxine than placebo starting from week 3 until the end of the study period, but no difference could be observed between fluoxetine and placebo. Baseline severity of psychic anxiety had a significant impact on remission rates after treatment of patients diagnosed with depression. Venlafaxine's superior remission rates in the more severely anxious patients and its ability to improve psychic anxiety as early as week 1 compared with fluoxetine suggest that venlafaxine's early efficacy on anxiety symptoms may be the basis for its superior efficacy in depression. Depression and Anxiety 16:4–13, 2002. © 2002 Wiley‐Liss, Inc.
- Open Access
- 25 September 2001
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 4 (03) , 279-298
Social anxiety disorder in review: two decades of progress
Social anxiety disorder (SAD) is among the most common of all psychiatric disorders. It presents with a lifetime prevalence rate of up to 16% in the
- 25 September 2001
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 4 (03) , 279-298
Open AccessSocial anxiety disorder in review: two decades of progress
Social anxiety disorder (SAD) is among the most common of all psychiatric disorders. It presents with a lifetime prevalence rate of up to 16% in the
- 1 February 2001
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 25 (2) , 337-345
Predictors of treatment response in patients with posttraumatic stress disorder
- 1 February 2001
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 25 (2) , 337-345
Predictors of treatment response in patients with posttraumatic stress disorder
- 1 July 2000
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 15 (4) , 227-231
Symptom-specific effects of fluoxetine in post-traumatic stress disorder
The selective serotonin reuptake inhibitors have become a first line treatment for post-traumatic stress disorder (PTSD). In a recent double-blind study in civilians, fluoxetine produced clinically and statistically significant effects on all general measures of PTSD. We examined the specific effects of fluoxetine versus placebo in the above mentioned study of PTSD clusters and individual symptoms. Individuals were included if they met criteria for PTSD according to the Structured Clinical Interview for DSM-III-R (SCID). Symptoms were assessed at sequential time points by the Structured Interview for PTSD (SIP), a clinician interview based assessment, and a self-report scale, the Davidson Trauma Scale (DTS). A total of 53 patients were included in the analysis. On the SIP and DTS, fluoxetine was found to produce statistically significant changes on all clusters. Significant effects for fluoxetine were noted on 10 items of the DTS, and 8 items of the SIP. The SIP and DTS had 6 items in common that were significant. Fluoxetine exerts a broad spectrum effect in reducing all the symptom clusters of PTSD in this sample. The symptoms of being physically upset at reminders of the trauma, avoiding thoughts of the trauma, having difficulty enjoying things, feeling distant / estranged, having a sense of foreshortened future, and impaired concentration, were the symptoms most responsive to the effects of treatment with fluoxetine on both scales.
- 1 July 2000
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 15 (4) , 227-231
Symptom-specific effects of fluoxetine in post-traumatic stress disorder
The selective serotonin reuptake inhibitors have become a first line treatment for post-traumatic stress disorder (PTSD). In a recent double-blind study in civilians, fluoxetine produced clinically and statistically significant effects on all general measures of PTSD. We examined the specific effects of fluoxetine versus placebo in the above mentioned study of PTSD clusters and individual symptoms. Individuals were included if they met criteria for PTSD according to the Structured Clinical Interview for DSM-III-R (SCID). Symptoms were assessed at sequential time points by the Structured Interview for PTSD (SIP), a clinician interview based assessment, and a self-report scale, the Davidson Trauma Scale (DTS). A total of 53 patients were included in the analysis. On the SIP and DTS, fluoxetine was found to produce statistically significant changes on all clusters. Significant effects for fluoxetine were noted on 10 items of the DTS, and 8 items of the SIP. The SIP and DTS had 6 items in common that were significant. Fluoxetine exerts a broad spectrum effect in reducing all the symptom clusters of PTSD in this sample. The symptoms of being physically upset at reminders of the trauma, avoiding thoughts of the trauma, having difficulty enjoying things, feeling distant / estranged, having a sense of foreshortened future, and impaired concentration, were the symptoms most responsive to the effects of treatment with fluoxetine on both scales.
- 1 July 2000
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 15, S13-S17
Defining an appropriate management strategy for social anxiety disorder
Social anxiety disorder is a chronic and disabling, yet treatable, condition. Effective treatment should alleviate the core domains of fear, anxiety and physiological symptoms, as well as reduce overall disability and improve social functioning. Response to treatment can, therefore, be assessed at a global level where overall improvement is considered, and at the level of individual symptoms. In considering the way in which response to treatment can be measured, this review also identifies several factors that may worsen the prognosis of social anxiety disorder. Clinical studies of monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), and benzodiazepines for the treatment of social anxiety disorder are presented and discussed. The accumulation of evidence supports the use of SSRIs as first line therapy for social anxiety disorder, and the majority of data come from well controlled studies of paroxetine. In line with the recommendations of the International Consensus Group on Depression and Anxiety, a strategy for the management of social anxiety disorder is provided.
- 1 July 2000
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 15, S13-S17
Defining an appropriate management strategy for social anxiety disorder
Social anxiety disorder is a chronic and disabling, yet treatable, condition. Effective treatment should alleviate the core domains of fear, anxiety and physiological symptoms, as well as reduce overall disability and improve social functioning. Response to treatment can, therefore, be assessed at a global level where overall improvement is considered, and at the level of individual symptoms. In considering the way in which response to treatment can be measured, this review also identifies several factors that may worsen the prognosis of social anxiety disorder. Clinical studies of monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), and benzodiazepines for the treatment of social anxiety disorder are presented and discussed. The accumulation of evidence supports the use of SSRIs as first line therapy for social anxiety disorder, and the majority of data come from well controlled studies of paroxetine. In line with the recommendations of the International Consensus Group on Depression and Anxiety, a strategy for the management of social anxiety disorder is provided.
- 1 March 2000
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 14 (2_suppl1) , S5-S12
Trauma: The Impact of Post-Traumatic Stress Disorder
Trauma has an enormous impact on both individuals and society as a whole. Recognition of the extent of this impact by the medical profession has been relatively slow but, with our growing appreciation of the prevalence of trauma exposure in civilian as well as combat populations, the true scale of trauma-related psychiatric consequences is beginning to emerge. It has been reported that more than 60% of men and 51% of women experience at least one traumatic event in their lifetimes. Of these, 8% and 20%, respectively, fall victim to post-traumatic stress disorder (PTSD) indicating that more women are at risk for developing PTSD. Individuals experience severe psychiatric stress that is compounded by significant comorbid illness. This impacts critically upon quality of life resulting in grave functional and emotional impairment. In addition, there is a detrimental cost to society with high financial and social consequences from the significantly elevated rates of hospitalization, suicide attempts and alcohol abuse.
- 1 March 2000
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 14 (2_suppl1) , S5-S12
Trauma: The Impact of Post-Traumatic Stress Disorder
Trauma has an enormous impact on both individuals and society as a whole. Recognition of the extent of this impact by the medical profession has been relatively slow but, with our growing appreciation of the prevalence of trauma exposure in civilian as well as combat populations, the true scale of trauma-related psychiatric consequences is beginning to emerge. It has been reported that more than 60% of men and 51% of women experience at least one traumatic event in their lifetimes. Of these, 8% and 20%, respectively, fall victim to post-traumatic stress disorder (PTSD) indicating that more women are at risk for developing PTSD. Individuals experience severe psychiatric stress that is compounded by significant comorbid illness. This impacts critically upon quality of life resulting in grave functional and emotional impairment. In addition, there is a detrimental cost to society with high financial and social consequences from the significantly elevated rates of hospitalization, suicide attempts and alcohol abuse.
- 1 January 1999
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 9 (3) , 135-137
Further psychometric assessment of the TOP-8: A brief interview-based measure of PTSD
The TOP-8 scale was developed as a brief, clinician-administered scale for use in assessing responses to treatment in patients with post-traumatic stress disorder. Further psychometric evaluation of the scale has now been undertaken and is reported and discussed here. Depression and Anxiety 9:135–137, 1999.
- 1 January 1999
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 9 (3) , 135-137
Further psychometric assessment of the TOP-8: A brief interview-based measure of PTSD
The TOP-8 scale was developed as a brief, clinician-administered scale for use in assessing responses to treatment in patients with post-traumatic stress disorder. Further psychometric evaluation of the scale has now been undertaken and is reported and discussed here. Depression and Anxiety 9:135–137, 1999.